drugset / Trial / NCT02436252
Study of DSP-7888 in Patients With Myelodysplastic Syndrome
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1/2, uncontrolled, open-label, multicenter study in patients with MDS for whom no effective therapies currently exist.
Timeline
- Start
- 2015-05
- Primary completion
- 2020-03
- Completion
- 2020-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ombipepimut-S | Vaccine | 3.5 mg | — |
| Subject | ombipepimut-S | Vaccine | 10.5 mg | — |